Women's Health Comprehensive Panel
One swab. A complete picture of vaginal health. 26 clinically validated organism targets and five built-in antimicrobial resistance markers, from a single collection — replacing fragmented, multi-order testing with one actionable result.
Seven reasons this replaces fragmented testing
Comprehensive by design
One panel covers protective flora, bacterial vaginosis, aerobic vaginitis, all seven clinically relevant Candida species, and six core STI organisms — ordered from a single vaginal or endocervical swab.
Resistance-informed prescribing
Qualitative detection of mecA, vanA/vanB, blaCTX-M, and M. genitalium macrolide-resistance mutations gives providers actionable results — not just organism lists — at the point of care.
Fewer send-outs, faster answers
Real-time PCR across every target from one collection reduces repeat visits, specimen handling, and time to a treatment decision.
Built for antimicrobial stewardship
Resistance-marker reporting aligns with CDC Core Elements of Outpatient Antibiotic Stewardship, supporting right-drug, right-duration prescribing rather than empiric treatment alone.
Specialized reflex testing available
Herpes Simplex 1&2, Treponema pallidum, and Haemophilus ducreyi are available as a reflex subsection when a lesion-based specimen is clinically indicated.
Dedicated prenatal GBS screening
Streptococcus agalactiae (GBS) is offered as a separate prenatal reflex, aligned with ACOG/CDC guidance for universal screening at 35–37 weeks gestation via vaginal-rectal swab.
High-risk HPV screening, molecular method
PCR-based genotyping for HPV 16 and 18 individually, plus 12 pooled high-risk types, supporting cervical cancer screening alongside — not instead of — the vaginitis and STI workup.
Eight panel subsections, one collection
| Category | Organisms / Targets | Why It Matters |
|---|---|---|
| Protective Flora (4 targets) | L. crispatus, L. gasseri, L. iners, L. jensenii | Healthy, Lactobacillus-dominant baseline — used to establish the flora ratio for BV interpretation. |
| BV-Associated Organisms (6 targets) | Atopobium (Fannyhessea) vaginae, BVAB-2, Gardnerella vaginalis, Megasphaera 1&2, Mobiluncus curtisii, M. mulieris | Anaerobic shift organisms driving bacterial vaginosis and biofilm formation. |
| Aerobic Vaginitis / Opportunistic (3 targets) | Enterococcus spp., Escherichia coli, Staphylococcus aureus | Facultative/aerobic organisms distinct from anaerobic BV — different treatment pathway. |
| Candida Species (7 targets) | C. albicans, C. dubliniensis, C. glabrata, C. krusei, C. lusitaniae, C. parapsilosis, C. tropicalis | Species-level identification to differentiate azole-sensitive from resistant Candida. |
| STI Organisms — Core Panel (6 targets) | Chlamydia trachomatis, Mycoplasma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, Trichomonas vaginalis, Ureaplasma urealyticum | Sexually transmitted organisms with reliable detection from a standard vaginal/endocervical swab. |
| STI — Reflex Panel (3 targets) | Herpes Simplex Virus 1 & 2, Treponema pallidum, Haemophilus ducreyi | Requires an active lesion specimen rather than a routine vaginal swab; ordered as a reflex or add-on. |
| Prenatal — GBS Reflex (1 target) | Streptococcus agalactiae (GBS) | Gestational-timing driven, not symptomatic workup; aligned with ACOG/CDC guidance for universal screening at 35–37 weeks gestation via vaginal-rectal swab. |
| High-Risk HPV Screening (3 targets) | HPV 16 (genotyped), HPV 18 (genotyped), 12 other high-risk types pooled (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) | Age-based cervical cancer screening, not a symptomatic or STI-reflex test. Specimen: cervical / liquid-based cytology. |
Note: Treponema pallidum PCR is a molecular adjunct only — standard syphilis diagnosis remains serologic (RPR/VDRL with treponemal confirmation).
Actionable results, not just organism lists
mecA — methicillin resistance (S. aureus)
vanA / vanB — vancomycin resistance (Enterococcus)
blaCTX-M — ESBL resistance (E. coli)
23S rRNA mutation — macrolide (azithromycin) resistance, M. genitalium
Resistance markers are reported qualitatively (Detected / Not Detected).
More than a pathogen list
Pathogen detection & load
Every organism reported with detection status.
Resistance marker flags
Qualitative Detected / Not Detected reporting.
Diet & lifestyle guidance
Patient-ready guidance included with results.
Stewardship-aligned notes
Supports right-drug, right-duration prescribing.
From swab to chairside report
Collect
A vaginal or endocervical swab — no invasive procedure.
Ship
Sample ships to our CLIA-certified, high-complexity lab.
Analyze
Real-time RT-PCR identifies and quantifies target organisms in one run.
Report
A patient-friendly report returns to your practice for the chart.